FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2326974888> ?p ?o ?g. }

• W2326974888 endingPage "79" @default.
• W2326974888 startingPage "72" @default.
• W2326974888 abstract "Background: This study was designed to clarify the influence of metformin on serum carbohydrate antigen 199 (CA199) levels and its associated factors in Chinese type 2 diabetes mellitus (T2DM) patients. Subjects and Methods: In total, 1,253 T2DM patients were enrolled, including a non-metformin group (n=616), a short-term metformin group (at least 1 week to 2 years; n=325), and a long-term metformin group (≥2 years; n=312). Their clinical and biochemical characteristics were collected and compared. After 1 year, the biochemical parameters were re-examined in 296 patients. Sex hormones were determined, and associations between CA199 and other variables were assessed. Results: At baseline, the incidence of abnormal CA199 levels was 14.7%, 8.9%, and 4.7% in the non-metformin, short-term metformin, and long-term metformin groups, respectively. CA199 levels in females were significantly higher than in males (P<0.01) and decreased significantly with the time of taking metformin (25.60±13.68 U/mL in non-metformin controls vs. 17.62±10.87 U/mL in the short-term group vs. 10.54±8.14 U/mL in the long-term group; P=0.000). The correlation and multiple stepwise regression analysis revealed that glycosylated hemoglobin, metformin, gender, total cholesterol, and follicle-stimulating hormone were independent impact factors on CA199 concentrations (all P<0.05). Binary logistic regression revealed that the risk of abnormal CA199 concentrations of the total population with short-term metformin or long-term metformin treatment decreased 11% (odds ratio=0.89; P=0.001) and 30% (odds ratio=0.70; P=0.000), respectively, at baseline. After a 1-year follow-up, the incidence of high CA199 level decreased in both the short-term and the long-term metformin group compared with that of controls (P<0.05). The extent of CA199 decrease in the long-term metformin group was the greatest (−17% vs. −4.9% in the short-term group vs. 3% in controls, P=0.000), and the group's risk of high blood CA199 level was reduced 67% (odds ratio=0.33; P=0.023). The reduction in women was more apparent than that in men (−18% vs. −5%, P=0.000). Conclusions: Metformin therapy reduced the CA199 level in Chinese T2DM patients, and its greatest decrease occurred in women with longer therapeutic time." @default.
• W2326974888 created "2016-06-24" @default.
• W2326974888 creator A5006593695 @default.
• W2326974888 creator A5016265908 @default.
• W2326974888 creator A5019319051 @default.
• W2326974888 creator A5035817027 @default.
• W2326974888 creator A5042894475 @default.
• W2326974888 creator A5043415956 @default.
• W2326974888 creator A5050475802 @default.
• W2326974888 creator A5054352845 @default.
• W2326974888 creator A5064915235 @default.
• W2326974888 creator A5066725248 @default.
• W2326974888 date "2015-02-01" @default.
• W2326974888 modified "2023-09-25" @default.
• W2326974888 title "Metformin Reduces Serum CA199 Levels in Type 2 Diabetes Chinese Patients with Time–Effect and Gender Difference" @default.
• W2326974888 cites W1872908291 @default.
• W2326974888 cites W1968802243 @default.
• W2326974888 cites W1979836928 @default.
• W2326974888 cites W1989848842 @default.
• W2326974888 cites W1998608669 @default.
• W2326974888 cites W2013099235 @default.
• W2326974888 cites W2026967508 @default.
• W2326974888 cites W2039896904 @default.
• W2326974888 cites W2062637797 @default.
• W2326974888 cites W2065732412 @default.
• W2326974888 cites W2089171551 @default.
• W2326974888 cites W2094883382 @default.
• W2326974888 cites W2110675408 @default.
• W2326974888 cites W2136383161 @default.
• W2326974888 cites W2163691729 @default.
• W2326974888 cites W2510708214 @default.
• W2326974888 cites W2590594928 @default.
• W2326974888 cites W290779198 @default.
• W2326974888 cites W51083587 @default.
• W2326974888 cites W71402341 @default.
• W2326974888 doi "https://doi.org/10.1089/dia.2014.0176" @default.
• W2326974888 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4321771" @default.
• W2326974888 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25548963" @default.
• W2326974888 hasPublicationYear "2015" @default.
• W2326974888 type Work @default.
• W2326974888 sameAs 2326974888 @default.
• W2326974888 citedByCount "6" @default.
• W2326974888 countsByYear W23269748882019 @default.
• W2326974888 countsByYear W23269748882020 @default.
• W2326974888 countsByYear W23269748882021 @default.
• W2326974888 countsByYear W23269748882022 @default.
• W2326974888 crossrefType "journal-article" @default.
• W2326974888 hasAuthorship W2326974888A5006593695 @default.
• W2326974888 hasAuthorship W2326974888A5016265908 @default.
• W2326974888 hasAuthorship W2326974888A5019319051 @default.
• W2326974888 hasAuthorship W2326974888A5035817027 @default.
• W2326974888 hasAuthorship W2326974888A5042894475 @default.
• W2326974888 hasAuthorship W2326974888A5043415956 @default.
• W2326974888 hasAuthorship W2326974888A5050475802 @default.
• W2326974888 hasAuthorship W2326974888A5054352845 @default.
• W2326974888 hasAuthorship W2326974888A5064915235 @default.
• W2326974888 hasAuthorship W2326974888A5066725248 @default.
• W2326974888 hasBestOaLocation W23269748882 @default.
• W2326974888 hasConcept C120665830 @default.
• W2326974888 hasConcept C121332964 @default.
• W2326974888 hasConcept C126322002 @default.
• W2326974888 hasConcept C134018914 @default.
• W2326974888 hasConcept C151956035 @default.
• W2326974888 hasConcept C156957248 @default.
• W2326974888 hasConcept C2777180221 @default.
• W2326974888 hasConcept C2780323712 @default.
• W2326974888 hasConcept C2908647359 @default.
• W2326974888 hasConcept C2910068830 @default.
• W2326974888 hasConcept C555293320 @default.
• W2326974888 hasConcept C61511704 @default.
• W2326974888 hasConcept C71924100 @default.
• W2326974888 hasConcept C90924648 @default.
• W2326974888 hasConcept C99454951 @default.
• W2326974888 hasConceptScore W2326974888C120665830 @default.
• W2326974888 hasConceptScore W2326974888C121332964 @default.
• W2326974888 hasConceptScore W2326974888C126322002 @default.
• W2326974888 hasConceptScore W2326974888C134018914 @default.
• W2326974888 hasConceptScore W2326974888C151956035 @default.
• W2326974888 hasConceptScore W2326974888C156957248 @default.
• W2326974888 hasConceptScore W2326974888C2777180221 @default.
• W2326974888 hasConceptScore W2326974888C2780323712 @default.
• W2326974888 hasConceptScore W2326974888C2908647359 @default.
• W2326974888 hasConceptScore W2326974888C2910068830 @default.
• W2326974888 hasConceptScore W2326974888C555293320 @default.
• W2326974888 hasConceptScore W2326974888C61511704 @default.
• W2326974888 hasConceptScore W2326974888C71924100 @default.
• W2326974888 hasConceptScore W2326974888C90924648 @default.
• W2326974888 hasConceptScore W2326974888C99454951 @default.
• W2326974888 hasIssue "2" @default.
• W2326974888 hasLocation W23269748881 @default.
• W2326974888 hasLocation W23269748882 @default.
• W2326974888 hasLocation W23269748883 @default.
• W2326974888 hasLocation W23269748884 @default.
• W2326974888 hasOpenAccess W2326974888 @default.
• W2326974888 hasPrimaryLocation W23269748881 @default.
• W2326974888 hasRelatedWork W2001756313 @default.
• W2326974888 hasRelatedWork W2005084305 @default.
• W2326974888 hasRelatedWork W2016264464 @default.

• next